Post job

FibroGen CEO and executives

Executive Summary. Based on our data team's research, Enrique A. Conterno is the FibroGen's CEO. FibroGen has 461 employees, of which 38 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The FibroGen executive team is 32% female and 68% male.
  • 56% of the management team is White.
  • 14% of FibroGen management is Hispanic or Latino.
  • 9% of the management team is Black or African American.
Work at FibroGen?
Share your experience

Rate FibroGen's leadership communication with employees.

Zippia waving zebra
Name & TitleBio
Enrique A. Conterno

CEO

Enrique A. Conterno's LinkedIn

Enrique Conterno joined FibroGen as CEO in 2020. Enrique Conterno is a senior vice president of Eli Lilly and Company and president of Lilly Diabetes. Enrique joined Lilly in 1992 and has held a range of roles in sales, finance, marketing, business development, and general management. He served as marketing and sales director for Lilly’s Peru and Brazil affiliates, as executive marketing director for the intercontinental region and Japan, and as general manager for Lilly Mexico. Enrique was vice president of the company’s U.S. neuroscience business unit and vice president for health care professional markets. He served as president of Lilly’s U.S. affiliate until he was named president of Lilly Diabetes in 2009. Enrique earned a bachelor’s degree in mechanical engineering from Case Western Reserve University and a master’s degree in business administration from Duke University. He serves on the board of the National Association of Manufacturers (NAM) and as treasurer for the Board of Directors of the Indy Chamber of Commerce. He is also on the Board of Visitors for Duke’s Fuqua School of Business.

Thomas Neff

Founder

Stephen Freke

Founder

James A. Schoeneck

Board Member

James A. Schoeneck's LinkedIn

Aoife M. Brennan

Board Member

Aoife M. Brennan's LinkedIn

Jeffrey L. Edwards

Board Member

Jeffrey William Henderson

Board Member

Jeffrey William Henderson's LinkedIn

Mark Eisner

Chief Medical Officer

Mark Eisner's LinkedIn

Mark Eisner is a Chief Medical Officer at FIBROGEN INC. He has worked as SR VP/Head:Product Development Immunology at Genentech. Mark studied at Stanford University, University of Pennsylvania, and University of California Berkeley.

Rory B. Riggs

Board Member

Thane Wettig

Chief Commercial Officer

Thane Wettig's LinkedIn

30 years of experience in sales, marketing and strategy with Eli Lilly and Company and Intarcia Therapeutics. 14 years as the marketing leader for Eli Lilly and Company's diabetes business; significant brand building, product launch, strategic marketing and alliance experience; deep diabetes and metabolic expertise. Currently Chief Commercial Officer at Intarcia Therapeutics with responsibility for launch preparation activities for our lead asset, ITCA 650, which is undergoing regulatory review by the FDA for the treatment of Type 2 diabetes.

Do you work at FibroGen?

Does leadership effectively guide FibroGen toward its goals?

FibroGen jobs

FibroGen founders

Name & TitleBio
Thomas Neff

Founder

Stephen Freke

Founder

FibroGen board members

Name & TitleBio
Enrique A. Conterno

CEO

Enrique A. Conterno's LinkedIn

Enrique Conterno joined FibroGen as CEO in 2020. Enrique Conterno is a senior vice president of Eli Lilly and Company and president of Lilly Diabetes. Enrique joined Lilly in 1992 and has held a range of roles in sales, finance, marketing, business development, and general management. He served as marketing and sales director for Lilly’s Peru and Brazil affiliates, as executive marketing director for the intercontinental region and Japan, and as general manager for Lilly Mexico. Enrique was vice president of the company’s U.S. neuroscience business unit and vice president for health care professional markets. He served as president of Lilly’s U.S. affiliate until he was named president of Lilly Diabetes in 2009. Enrique earned a bachelor’s degree in mechanical engineering from Case Western Reserve University and a master’s degree in business administration from Duke University. He serves on the board of the National Association of Manufacturers (NAM) and as treasurer for the Board of Directors of the Indy Chamber of Commerce. He is also on the Board of Visitors for Duke’s Fuqua School of Business.

James A. Schoeneck

Board Member

James A. Schoeneck's LinkedIn

Aoife M. Brennan

Board Member

Aoife M. Brennan's LinkedIn

Jeffrey L. Edwards

Board Member

Jeffrey William Henderson

Board Member

Jeffrey William Henderson's LinkedIn

Rory B. Riggs

Board Member

Thomas F. Kearns

Board Member

Thomas F. Kearns's LinkedIn

Gerald Lema

Board Member

Gerald Lema's LinkedIn

Suzanne Blaug

Board Member

Suzanne Blaug's LinkedIn

Ben F. Cravatt

Board Member

FibroGen leadership demographics

FibroGen gender distribution in management team

  • The FibroGen executive team is 32% female and 68% male.
  • FibroGen is 44% female and 56% male company-wide.
Male
Male
68%
Company-wide: 56%
Female
Female
32%
Company-wide: 44%

FibroGen executives by race

Management Team:
  • The most common ethnicity among FibroGen executive officers is White.
  • 56% of the management team is White.
  • 18% of FibroGen's management is Asian.
  • 14% of the management team is Hispanic or Latino.
Company-wide:
  • White is the most common ethnicity company-wide.
  • 42% of employees are White.
  • 26% of employees are Asian.
  • 21% of employees are Hispanic or Latino.
  • Management team
  • General
100%
80%
60%
40%
20%
0%
Unknown
White
Black or African American
Asian
Hispanic or Latino

FibroGen jobs nearby

FibroGen executives FAQs

Zippia gives an in-depth look into the details of FibroGen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about FibroGen. The employee data is based on information from people who have self-reported their past or current employments at FibroGen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by FibroGen. The data presented on this page does not represent the view of FibroGen and its employees or that of Zippia.

FibroGen may also be known as or be related to FIBROGEN INC, FibroGen, FibroGen Inc, FibroGen, Inc. and Fibrogen, Inc.